Intraperitoneal Chemotherapy Extends Ovarian Cancer Survival by Year
4th Jan 2006, 23:46 GMT
BALTIMORE - Intraperitoneal Taxol (paclitaxel) and Platinol (cisplatin) combined with intravenous chemotherapy significantly prolonged both progression-free and overall survival in women with optimally debulked stage III ovarian cancer.
Intraperitoneal Chemotherapy Extends Ovarian Cancer Survival by Year related news:
- Experts: Study brings big advance against ovarian cancer — KVOA - KVOA 4 News
- Study Brings Advance With Ovarian Cancer — AP Top Headlines At 5 p.m. EST
- Study Sees Benefit in High-Dose Chemotherapy for Breast Cancer (American Cancer Society) — Yahoo! Health: Breast Cancer News
- The English might be on to something with that tea — The Cancer Blog
- Fabulous, thoughtful gifts for female related cancers — The Cancer Blog
- More Colon Cancer Patients Get Chemotherapy (HealthDay) — Yahoo! Health: Chemotherapy News
- Chemo, Radiation Beat Back 2nd Round of Head, Neck Cancers (HealthDay) — Yahoo! Health: Chemotherapy News
- Abdominal-site chemo zaps ovarian cancer — United Press International - Health Business
- Chemotherapy Boosts Cancer Vaccine's Punch (HealthDay) — Yahoo! Health: Chemotherapy News
- Iressa Doesn't Improve Odds Against Lung Cancer (HealthDay) — Yahoo! Health: Chemotherapy News